DUBLIN–(BUSINESS WIRE)–The “Cell Reprogramming Market Share, Size, Trends, Industry Analysis Report, By Technology, By Application, By End-Use, By Region, Segment Forecast, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.
The global cell reprogramming market size is expected to reach USD 618.00 million by 2030 according to a new study. The report “Cell Reprogramming Market Share, Size, Trends, Industry Analysis Report, By Technology (Sendai Virus, mRNA, Episomal); By Application (Research, Therapeutic); By End-Use; By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Cell reprogramming has gained traction for its capability to replace damaged cells or tissues, thereby reversing the adverse physiological effects it causes. Advancements in related technologies like the creation of progenitor cells, gene editing, and tissue engineering have driven the growth of the market.
Cellular reprogramming also has a significant impact on diagnosing and addressing human diseases. The increasing interest drives the market among researchers in the field because it makes it possible to evaluate molecular biological mechanisms like epigenetics, chromatin, and differentiation in previously impossibly complex ways.
Regenerative medicine for providing a viable treatment advancement in stem cell biology, and increasing relevancy of cell reprogramming in the healthcare sector, propels the growth of the market. Regulatory networks play a crucial role, such as Oct4 is generally considered the master gene for maintaining the pluripotent state of ES cells.
The covid-19 pandemic positively impacted the market. The researchers were involved in developing novel medications and treatments to fight against Covid, increasing the use of cell reprogramming methods to produce personalized drugs. Also, increased governmental and private player investments have driven the market’s growth.
Cell Reprogramming Market Report Highlights
Based on technology, mRNA reprogramming is anticipated to have the most significant market share as it produces reprogramming efficiency more significantly than 1% without the use of virus or DNA vectors.
The use of mRNA during reprogramming obligates the need for the CMYC oncogene, making the generation of iPSCs safer. Their role as reprogramming enhancers allows mRNAs to increase reprogramming efficacy and decrease the number of transfections required in conjunction with mRNAs.
The research segment is anticipated to account for a significant share as governments and private groups are investing in stem cell research studies, enhancing industrial participants, and creating a secure position for themselves in the global sector by treating various chronic conditions.
An increasing number of strategic efforts for research and method for innovative products from cell reprogramming has driven the research and academic institute growth and is accounted for the largest market share propelling the cell programming market.
North America is anticipated to account for the largest market share as medical research has increased in the U.S., resulting increasing need for innovative treatment options.
The publisher has segmented the cell reprogramming market report based on form, application, end use and region:
Cell Reprogramming, Technology Outlook (Revenue – USD Million, 2018 – 2030)
Sendai-virus based reprogramming
mRNA reprogramming
Episomal reprogramming
Others
Cell Reprogramming, Application Outlook (Revenue – USD Million, 2018 – 2030)
Research
Therapeutics
Cell Reprogramming, End-Use Outlook (Revenue – USD Million, 2018 – 2030)
Research and Academic Institutes
Bio-technology and Pharmaceutical company
Hospitals and Clinics
Cell Reprogramming, Regional Outlook (Revenue – USD Million, 2018 – 2030)
North America
U.S
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Research Methodology
4. Global Cell Reprogramming Market Insights
5. Global Cell Reprogramming Market, by Technology
6. Global Cell Reprogramming Market, by Application
7. Global Cell Reprogramming Market, by End-Use
8. Global Cell Reprogramming Market, by Geography
9. Competitive Landscape
10. Company Profiles
Companies Mentioned
Allele Biotechnology
ALSTEM
Applied Biological Materials
Axol Bioscience
Creative Bioarray
DefiniGEN
Fujifilm Cellular Dynamics
Lonza
Mogrify
REPROCELL
Stemnovate
Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/r/ljvpgl
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
